This is a three group study on the effectiveness and safety of Curcuma caesia for weight management.

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 36

Inclusion Criteria

1 Male and/or female patients.

2 Age between 20 to 55 years.

3 BMI between greater than 35 to 40 kg/m2.

4 Willing to come for regular follow up visits.

5 Able to give written informed consent.

Exclusion Criteria

1 Intake of over the counter weight loss agents, centrally acting appetite suppressants in the previous six months.

2 Pathophysiologic or genetic syndromes associated with obesity like Cushingâ??s syndrome, Turnerâ??s syndrome, Praderwilli syndrome.

3 Patients with evidence of malignancy.

4 History of poorly controlled Diabetes Mellitus. Glycosylated haemoglobin greater than 10 percent.

5 Patients on prolonged greater than 6 weeks medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.

6 Symptomatic patient with clinical evidence of Heart failure.

7 History of HIV and other viral infections.

8 Prior surgical therapy for obesity.

9 History of hypersensitivity to any of the herbal extracts or dietary supplement.

10 Pregnant or lactating woman.

11 Patients who have completed participation in any other clinical trial during the past six months.

12 Any other condition which the Principal Investigator thinks may jeopardize the study.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1 Change in body weight and BMI. <br/ ><br>2 Change in DEXA analysis. <br/ ><br>3 Change in Lipid Profile. <br/ ><br>4 Change in anthropometric measurements. <br/ ><br>5 Clinical Photographs.Timepoint: 1 Change in body weight and BMI(Screening,Day30,Day60 and Day90). <br/ ><br>2 Change in DEXA analysis(Day0 and Day90). <br/ ><br>3 Change in Lipid Profile(Screening and Day90). <br/ ><br>4 Change in anthropometric measurements(Baseline,Day30,Day60 and Day90). <br/ ><br>5 Clinical Photographs(Screening and Day90).

Secondary Outcome Measures

Name	Time	Method
1 Adverse Events. <br/ ><br>2 Serious Adverse Events. <br/ ><br>3 Abnormal Vital Signs. <br/ ><br>4 Abnormal Laboratory Investigations.Timepoint: 1 Adverse Events(Day30,Day60,Day90 and follow up). <br/ ><br>2 Serious Adverse Events(Day30,Day60,Day90 and follow up). <br/ ><br>3 Abnormal Vital Signs(Screening,Day0,Day30,Day60 and Day90). <br/ ><br>4 Abnormal Laboratory Investigations(Screening and Day90).